Multiply Labs & AstraZeneca Collaborate to Automate Cell Therapy Manufacturing

Multiply Labs and AstraZeneca have joined forces to revolutionize cell therapy manufacturing through advanced robotics. The collaboration, announced today, will evaluate Multiply Labs’ GMP-ready robotic systems for scaling up production of these complex, yet promising, medicines. Multiply Labs’ technology utilizes multi-arm robotic clusters – systems with four robotic arms operating in parallel – to automate industry-standard instruments, aiming to boost output without compromising quality or regulatory standards. “Our mission is to make these therapies more widely available by increasing manufacturing efficiency and scale,” says Fred Parietti, PhD, CEO of Multiply Labs. This partnership signals a significant step towards overcoming manufacturing bottlenecks and delivering potentially life-saving cell therapies to more patients.

AstraZeneca Collaboration Scales GMP-Ready Robotic Cell Therapy

Multiply Labs, a San Francisco-based robotics company, is collaborating with AstraZeneca to address critical manufacturing hurdles in cell therapy production. The agreement centers on evaluating Multiply Labs’ “GMP-ready robotic systems” for commercial-scale application, aiming to increase efficiency and output for these complex medicines. Multiply Labs’ technology utilizes robotic clusters featuring four parallel arms, designed to operate with existing industry-standard cell therapy manufacturing instruments—reducing the need for extensive process changes while boosting productivity. “Cell therapies are among the most promising, yet complex medicines being developed today,” explains Fred Parietti, PhD, CEO of Multiply Labs.

This partnership seeks to establish scalable, high-throughput manufacturing processes that simultaneously adhere to stringent clinical and regulatory requirements. Multiply Labs’ systems are cloud-controlled and built by a team encompassing mechanical, electrical, and software engineers alongside pharmaceutical scientists, originating from a shared passion for robotics at MIT.

Multiply Labs’ Multi-Arm Robotics Boost Manufacturing Throughput

Multiply Labs is tackling a critical bottleneck in advanced medicine: the manufacturing of cell therapies. The San Francisco-based robotics company announced on November 29, 2023, an agreement with AstraZeneca to assess the application of robotic systems for commercial-scale production. The collaboration will concentrate on automating industry-standard instruments used in cell therapy production, leveraging Multiply Labs’ robotic biomanufacturing system. By maintaining rigorous quality and regulatory standards, the partnership seeks to establish scalable, high-throughput processes, potentially transforming access to these cutting-edge treatments for patients.